amplification of the exons 5\p=n-\9 of the p53 gene followed by single strand conformation polymorphism (SSCP) SSCP analysis for the detection of mutations in codons [12] [13] and 61 of ras genes (N-ras, Ha-ras and Ki-ras) was performed as described (18) . Analysis of the activation of RET and TRK oncogenes was performed as described (19) (20) .
Gel purified PCR products were utilized as template in direct sequencing reactions. When a mutated sample was identified, the mutation was confirmed by cloning the PCR product in the plasmid vector pT7blue (Novagen) and sequencing 12 independent clones with the Sequenase kit (USB) using plasmid primers T7 and U19.
Immunohistochemistry
Immunostaining was performed, essentially as described elsewhere (12, 14, (Fig. IB) . Moreover (12, 14) . We confirmed the presence of p53 mutations in the two samples previously described by immunohistochemistry. Positive immunostaining at the nuclear level was observed in these two cases, when both polyclonal anti-p53 antibody CM-1 (an example is shown in Fig. 2) (35) . Moreover, combination of p53 and c-Ki-ras alterations have also been described in pancreatic adenocarclnomas (36) . In vitro cell systems demon¬ strate a cooperative effect between p53 and ras mutations; co-transfection of mutated p53 and activated ras oncogenes into primary fibroblasts leads to full cellular transformation (37) . The (38) .
Preliminary data from our laboratory confirm the association of p53 mutations and loss of differentiated phenotype of cultured thyroid cells (39) . In addition, the availability of the B-CPAP, expressing both p53 and a cKi-ras mutated alíeles, will allow studies able to clarify the role of these mutations in the transformation and blockage of the thyroid differentiated phenotype.
